CN103619883A - 凝血因子抑制剂的结合蛋白 - Google Patents

凝血因子抑制剂的结合蛋白 Download PDF

Info

Publication number
CN103619883A
CN103619883A CN201280014817.3A CN201280014817A CN103619883A CN 103619883 A CN103619883 A CN 103619883A CN 201280014817 A CN201280014817 A CN 201280014817A CN 103619883 A CN103619883 A CN 103619883A
Authority
CN
China
Prior art keywords
antibody
fab
cdr
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280014817.3A
Other languages
English (en)
Chinese (zh)
Inventor
F·迪特默
A·布奇穆勒
C·格德斯
A·特尔斯迪根
M·J·格诺斯
L·林登
A·哈伦加
J·格鲁德金斯卡-高宝
M·杰斯科
M·沙弗尔
J·博肯费尔德
H·鲍尔森
R·芬纳恩
A·迈耶-巴奇米德
A·埃克尔
S·格利文
S·斯泰尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN103619883A publication Critical patent/CN103619883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280014817.3A 2011-01-19 2012-01-17 凝血因子抑制剂的结合蛋白 Pending CN103619883A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11151410.5 2011-01-19
EP11151410 2011-01-19
PCT/EP2012/050595 WO2012098089A1 (en) 2011-01-19 2012-01-17 Binding proteins to inhibitors of coagulation factors

Publications (1)

Publication Number Publication Date
CN103619883A true CN103619883A (zh) 2014-03-05

Family

ID=45491612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280014817.3A Pending CN103619883A (zh) 2011-01-19 2012-01-17 凝血因子抑制剂的结合蛋白

Country Status (7)

Country Link
US (1) US20140050743A1 (https=)
EP (1) EP2665751A1 (https=)
JP (1) JP2014506448A (https=)
CN (1) CN103619883A (https=)
AR (1) AR084886A1 (https=)
CA (1) CA2824885A1 (https=)
WO (1) WO2012098089A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248964A (zh) * 2017-02-01 2019-09-17 诺和诺德股份有限公司 促凝血抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051158A1 (en) * 2000-04-20 2001-12-13 Owens Samuel M. Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2010056765A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
RU2319699C2 (ru) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Производные диаминов
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051158A1 (en) * 2000-04-20 2001-12-13 Owens Samuel M. Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2010056765A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EIGENBROT C ET AL.: "Structural Insight into How An Anti-idiogypic Antibody Against D3H44(Anti-tissue Coagulation)", 《JOURNAL OF MOLECULAR BIOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248964A (zh) * 2017-02-01 2019-09-17 诺和诺德股份有限公司 促凝血抗体
US12084512B2 (en) 2017-02-01 2024-09-10 Novo Nordisk A/S Procoagulant antibodies

Also Published As

Publication number Publication date
JP2014506448A (ja) 2014-03-17
CA2824885A1 (en) 2012-07-26
AR084886A1 (es) 2013-07-10
US20140050743A1 (en) 2014-02-20
EP2665751A1 (en) 2013-11-27
WO2012098089A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
US10407496B2 (en) Compositions and methods for antibodies targeting complement protein C5
CA2822515C (en) Anti-il-18 antibodies and their uses
US20100291106A1 (en) Compositions and methods for antibodies targeting complement protein c3b
AU2014281294A1 (en) Lectin-like oxidized LDL receptor1 antibodies and methods of use
US20240279322A1 (en) Isoform-selective anti-tgf-beta antibodies and methods of use
CN103619883A (zh) 凝血因子抑制剂的结合蛋白
US20210395390A1 (en) Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
US12215168B2 (en) Anti-A2AP antibodies and uses thereof
JP2025510815A (ja) 抗ｐａｒ２抗体
TW201245226A (en) Binding proteins to inhibitors of coagulation factors
HK1190726A (en) Binding proteins to inhibitors of coagulation factors
RU2844816C1 (ru) Новые антитела против a2ap и их применение
BR112023002800B1 (pt) Anticorpos anti-a2ap e seu método de produção, conjugado deanticorpo, sequências de ácido nucleico isoladas, vetor, composiçãofarmacêutica, seu uso, e kit
HK40082595A (en) Isoform-selective anti-tgf-beta antibodies and methods of use
HK40010475B (zh) Gremlin-1晶体结构和抑制性抗体
HK40010475A (en) Gremlin-1 crystal structure and inhibitory antibody
HK1156226B (en) Compositions and methods for antibodies against complement protein c5
HK1202269B (en) Compositions and methods for antibodies targeting complement protein c5

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190726

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20170412

AD01 Patent right deemed abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1190726

Country of ref document: HK